Armata Pharmaceuticals (ARMP) Total Liabilities (2013 - 2026)

Armata Pharmaceuticals (ARMP) has 14 years of Total Liabilities data on file, last reported at $381.4 million in Q1 2026.

• For the quarter ending Q1 2026, Total Liabilities rose 170.42% year-over-year to $381.4 million; the trailing twelve-month figure through Mar 2026 stood at $381.4 million (up 170.42% YoY), and the FY2025 full-year result was $295.5 million, up 119.76% from the prior year.
• Total Liabilities grew to $381.4 million in Q1 2026, from $295.5 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $381.4 million in Q1 2026 to a low of $46.2 million in Q1 2022.
• A 5-year average of $140.8 million and a median of $134.5 million in 2024 frame the typical range for Total Liabilities.
• Across the five-year window, Total Liabilities declined 20.26% in 2025 and surged 170.42% in 2026, its largest moves.
• Tracing ARMP's Total Liabilities over 5 years: stood at $59.8 million in 2022, then surged by 118.27% to $130.4 million in 2023, then gained by 3.09% to $134.5 million in 2024, then soared by 119.76% to $295.5 million in 2025, then advanced by 29.07% to $381.4 million in 2026.
• Business Quant data shows ARMP's Total Liabilities at $381.4 million in Q1 2026, $295.5 million in Q4 2025, and $185.1 million in Q3 2025.